Should You Buy Design Therapeutics Inc (DSGN) Stock After it Has Gained 14.42% in a Week?

Design Therapeutics Inc (DSGN) stock has risen 14.42% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Design Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on DSGN!

See Full DSGN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With DSGN Stock Today?

Design Therapeutics Inc (DSGN) stock is trading at $2.38 as of 3:03 PM on Wednesday, Aug 30, a gain of $0.07, or 3.03% from the previous closing price of $2.31. The stock has traded between $2.28 and $2.44 so far today. Volume today is low. So far 884,912 shares have traded compared to average volume of 1,428,516 shares. To see InvestorsObserver's Sentiment Score for Design Therapeutics Inc click here.

More About Design Therapeutics Inc

Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Click Here to get the full Stock Report for Design Therapeutics Inc stock.